在肺腺癌中,TFF3驱动Hippo依赖的EGFR-TKI耐药性

Shuwei Zhang1, Yan Qin Tan1,2, Xi Zhang3

  • 1Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, 518055, PR China.

Oncogene
|December 10, 2024
PubMed
概括

三叶草因子3 (TFF3) 在肺腺癌 (LUAD) 中驱动对表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 治疗的耐药性. 抑制TFF3可以克服这种耐药性,改善LUAD治疗结果.